Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma

00:04 EDT 21 Jul 2018 | ChinaBio Today

Laurel Venture Capital, a Hangzhou life science VC, acquired global rights to novel asthma/COPD drug technology from Alpine Immune Sciences of Seattle. Laurel intends to form a China company to develop the technology. The agreement includes global rights to cavosonstat, Alpine's lead drug that is currently in a US Phase II trial. Laurel plans to expand the trial into a global test. Laurel will make an upfront payment and pay future milestones and royalties, though details were not disclosed. More details....

Share this with colleagues:

Original Article: Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma


More From BioPortfolio on "Laurel VC Acquires Asthma/COPD Technology; Will Form China Biopharma"

Quick Search


Relevant Topics

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...